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Abstract 
G protein-coupled receptors are expressed on the surface of eukaryotic cells and internalise 
in response to ligand binding.  The actions of the hormone and neurotransmitter neurotensin 
(NT) are predominantly mediated by specific interactions with one such receptor. Neurotensin 
receptor 1 (NTS1), which is upregulated in a variety of cancers, including pancreatic and 
breast tumours. NTS1 could therefore serve as a target for selective delivery of therapeutics. 
This study characterised the expression of NTS1 in HEK293 cells, as well as both polarised 
and non-polarised intestinal epithelial Caco-2 cells. NT-conjugated fluorophores were 
internalised in NTS1-expressing HEK293 and Caco-2 cells in a receptor-mediated fashion.  
Confocal microscopy revealed fluorophore localisation in the perinuclear region. Cell uptake 
and transport across the Caco-2 intestinal model of two NT-conjugated fluorophores (GFP 
and fluorescein) were compared to evaluate the effect of cargo size on cellular uptake. This 
work demonstrates that NT ligand conjugation is able to deliver relatively large 
macromolecular cargoes selectively into cells overexpressing NTS1 and the system is able to 
effectively translocate macromolecules across an intestinal epithelial model. NTS1 therefore 
shows potential as a drug delivery target not only for targeted but also non-invasive (oral) 
delivery of biotherapeutics for cancer.  
 
Keywords 
Caco-2, Neurotensin, Neurotensin Receptor 1, Peptide-guided drug delivery, Targeted drug 
delivery. 
 
Abbreviations 
DAPI – 4',6-diamidino-2-phenylindole. 
DMEM – Dulbecco’s Modified Eagles Medium. 
DOTA – 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. 
F – fluorescein. 
FBS – foetal bovine serum. 
F-NT – N-terminally fluorescein-labelled neurotensin. 
Fluo-NT – fluorescently-labelled neurotensin. 
GFP – green fluorescent protein. 
GFP-NT - green fluorescent protein with an N-terminal hexahistidine tag and C-terminal 
neuroetensin fusion. 
His6 – hexahistidine tag. 
His-GFP – green fluorescent protein with an N-terminal hexahistidine tag. 
HBSS – Hank’s Balanced Salt Solution. 
NT – neurotensin. 
NTS1 – neurotensin receptor 1. 
NTS2 – neurotensin receptor 2. 
NTS3 – neurotensin receptor 3. 
TEER – transepithelial electrical resistance. 
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Introduction  
 
Targeted delivery of therapeutics to diseased tissue as a means of increasing the therapeutic 
benefits of a drug, including reduction of adverse effects [1], is a key aim of modern 
pharmaceutics. A range of options are available to guide the drug to the cells or tissue of 
interest, exploiting disease-induced changes in biology as a basis for selectivity. Aberrantly or 
overexpressed cell-surface receptors offer an attractive route for targeted drug delivery in 
cancer [2].  Neurotensin (NT) is a tridecapeptide known to exert a variety of effects; it has a 
dual role as both a neuromodulator in the central nervous system and as a local hormone in 
the periphery [3]. The actions of NT are mediated by specific interactions with one of three 
receptors, the first two being G protein-coupled receptors (GPCRs): NTS1, NTS2 and NTS3, 
all of which are known to internalise upon interaction with NT [4].  NTS1 is thought to play the 
predominant role in eliciting the actions of NT and is the main focus of this study. NTS1 is 
known to be upregulated in a variety of different cancer types, including pancreatic and breast 
tumours [5] and has been demonstrated to be a key driver of cell proliferation, survival, 
migration and invasion (reviewed in [6]).  Indeed, NTS1 antagonists have been proposed as 
anti-cancer agents, but currently-available drugs exhibit significant toxicity [6]. 
 
An alternative approach to the development of such drugs is the use of NTS1 as a molecular 
target for drug delivery [5-8].  The underpinning theory is that the receptor-ligand-drug 
complex will internalise, delivering drugs in a targeted manner.  Initial studies demonstrated 
the viability of this approach (reviewed in [6])  and the potential of NT as a drug delivery 
ligand has been documented recently. Jia et al., (2015) [9] investigated the rates of 
internalisation of NT conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
(DOTA), used for radiotherapy. This study found that the use of a spacer (β-Alanine) between 
NT and DOTA increases the internalisation rates of NT analogues, mediated by NTS1, 
compared to conjugation without a spacer. This reflects the work of Antunes et al.  [10] that 
documents the effect of spacers between somatostatin analogues and radiolabelled DOTA. 
Other work has used synthetic oligobranched NT conjugates to deliver cargoes to cells, 
including doxorubicin-loaded liposomes [11] and methotrexate or gemcitabine [12], as well as 
oligobranched NT derivatives to target NT receptors [12-14].  However, little is known of the 
molecular mechanism underpinning NTS1 internalisation or the limitations on the size and 
nature of cargo which can be delivered.  This is of increasing importance as many recently-
developed anticancer therapeutics are biologics. 
 
NT provides a suitable ligand for targeted delivery as it interacts with the NTS1 receptor with 
high affinity (Kd 0.3-1 nM) [15] and only its six C-terminal amino acids are required for 
receptor binding [16], which allows covalent or translational attachment of a variety of 
macromolecules to the N-terminus. In most cell types, receptor-mediated peptide 
internalisation results in fusion with lysosomes and degradation [17]. However, internalisation 
of NT has been shown to follow a different route. Vandenbulcke et al., (2000) investigated the 
method of internalisation of fluorescently labelled NT (Fluo-NT) in COS-7 cells transfected 
with NTS1 and demonstrated, by methods of pathway-selective inhibition (hypertonic 
sucrose, potassium depletion and cytosol acidification), that NT internalisation is mediated by 
clathrin coated pits [18]. Importantly, NT and NTS1 appear to separate on internalisation and 
Fluo-NT was demonstrated to traffic to the transgolgi network [18]. This provides a possible 
lysosome-escape route for macromolecules tagged with NT, mitigating lysosome degradation 
as one of the key problems of intracellular drug delivery. This makes the NT/NTS1 cell entry 
pathway a particularly attractive option for therapeutic delivery.  However, NT also has a short 
serum half-life (minutes) but this can be mitigated by modifications to the peptide [19, 20].  In 
this study, we have focussed on native NT as proof of concept due to its well-characterised 
biological action and the ease of producing NT-macromolecule complexes.  This allows us to 
characterise the properties of NTS1 internalisation, but future translational work should focus 
on stable analogues. 
 
Here, we demonstrate that NTS1 can be used to internalise payloads of different sizes, 
namely a relatively small fluorophore or macromolecular GFP. Efficient internalisation of 
these cargoes is observed in HEK293 cells expressing NTS1 and this uptake is significantly 
attenuated via competition with either receptor agonists or antagonists. Importantly, we 
demonstrated efficient uptake into, and transport across, an intestinal epithelial model 
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consisting of polarised Caco-2 monolayers, which endogenously express NTS1. This study 
demonstrates for the first time that in addition to its potential as a targeting moiety for efficient 
and receptor-mediated uptake of macromolecules specifically into cells expressing or 
overexpressing its receptor(s) (e.g. cancer), NT is also able to ferry the cargo transintestinally 
in a receptor-mediated fashion, hence also demonstrating potential for oral delivery of 
macromolecules.  This addresses a significant challenge in the field [21]. 
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Materials and Methods 
 
Materials 
Caco-2 cells were obtained from the European Collection of Cell Cultures (ECACC) and were 
used between passages 60-80. HEK293 cells were obtained from the American Type Culture 
Collection (ATCC) and were used between passages 25-40. Dulbecco’s Modified Eagles 
Medium (DMEM; with 4500mg/L glucose, L-glutamine, sodium pyruvate and sodium 
bicarbonate), Hank’s Balanced Salt Solution (HBSS; with sodium bicarbonate and without 
phenol red), Trypsin/EDTA solution (0.25% trypsin, 0.02% EDTA), antibiotic/antimycotic 
solution (penicillin, streptomycin and amphotericin), foetal bovine serum (FBS, non-USA 
origin), dimethylsulphoxide (DMSO), trypan blue solution (0.4% solution) and poly-l-lysine 
(0.1% solution, mw = 70,000-15,000) were all obtained from Sigma Aldrich (UK). DMEM was 
supplemented with 10% FBS and 1% antibiotic/antimycotic solution to produce complete 
DMEM. Transwell
®
 permeable supports of 12 mm diameter and 0.4 μm pore size (polyester 
membrane) were obtained form Corning Life Sciences (USA). Human neurotensin was 
supplied by Sigma Aldrich and SR142948 (non-peptide NTS1 and NTS2 receptor antagonist) 
were obtained from Tocris Bioscience
© 
(UK). Protease inhibitor tablets (cOmplete™ protease 
inhibitor cocktail tablets, EDTA-free) were supplied by Roche Diagnostics (USA). 
 
Methods 
GFP-NT and GFP synthesis  
A translational fusion of His-GFP and NT was produced by sequential PCR (AG1 and AG3, 
AG2 and AG4, AG2 and AG5) on a clone of Emerald GFP to extend the C-terminus to 
encode NT and the N-terminus to encode a His6 tag. The primers used are illustrated in Table 
1. The final PCR product was digested with NdeI/BamHI and cloned into NdeI/BamHI 
digested pET17b. pET17b-GFP was produced by Quikchange mutagenesis using primers 
AG6 and AG7 to introduce a stop codon prior to the NT coding sequence in pET17b-GFP-NT.  
GFP-NT and GFP were produced by recombinant expression in E. coli BL21(DE3) grown in 
LB broth containing 100 g/ml ampicillin, followed by cell lysis using pulsed sonication (5 
minutes, 5s on, 5s off) in 50 mM Tris, 100 mM NaCl pH7.4 at 2ml per litre of culture.  
Purification was achieved via Immobilised Metal Affinity Chromatography using 1 ml HisTrap 
HP columns (GE Healthcare Life Sciences). Briefly, the column was equilibrated with 5 
column volumes (CV) 50 mM Tris, 100 mM NaCl pH7.4 followed by sample loading. The 
column was then washed with 10 CV of the same buffer also containing 50 mM imidazole.  
Proteins were eluted using the same buffer containing 200 mM imidazole. Protein purity was 
assessed via SDS-PAGE and quantitated via UV-Vis spectrophotometry. All proteins used 
were >95% pure. 
 
Cell culture  
Caco-2 and HEK293 cell lines were routinely cultured in 75cm
2 
flasks at 5% CO2, 95% 
relative humidity and 37°C in DMEM. Caco-2 cells were seeded on Transwell
®
 filter at a 
seeding density of 1x10
5
 per well and cultured for 21-24 days, with medium replacement 
every two days. Transepithelial Electrical Resistance (TEER) was measured to monitor Caco-
2 cell growth, polarisation and cell monolayer integrity. HEK293 cells are weakly adherent 
and were therefore cultured on poly-l-lysine (0.1% w/v) coated coverslips in 12-well plates. 
 
HEK293 transfection  
HEK293 cells cultured in 12-well plates were transfected using Lipofectamine® 2000 
Transfection reagent and the NTS1 containing plasmid (pcDNA3.1-NTS1, cDNA.org). This 
procedure used 4μl Lipofectamine and 1μg DNA per well. Lipofectamine and DNA (in 
medium) were incubated at room temperature for 60 minutes to form DNA-containing 
liposomes. Cell medium was replaced with reduced serum media (5% FBS) and the 
transfection mixture was then applied, followed by cell incubation at 5% CO2, 95% relative 
humidity and 37°C for 24 hours before use in experiments.  
 
Immunostaining  
Caco-2 cells were cultured on Transwell
®
 permeable inserts for 21 days and evaluated for 
monolayer integrity by TEER measurements. Cell monolayers were fixed with 4% w/v 
paraformaldehyde in PBS and washed 3 times with PBS.  Cells were then incubated for one 
hour with 1% w/v bovine serum albumin (BSA) in PBS at room temperature as a non-specific 
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binding blocking step. A 1:5000 dilution of the primary antibody (Rabbit Anti-Human NTS1; 
Sigma Aldrich (UK)) was prepared in 1% w/v BSA in PBS, as recommended by the supplier, 
and applied to fixed cell monolayers for one hour at room temperature. Primary antibody 
solution was omitted for the negative controls and cells were incubated with the antibody 
diluent solution (BSA). Each monolayer was then washed thoroughly with PBS and incubated 
for one hour with goat, anti-rabbit AlexaFluor
®
488 at 1:800 dilution in 1% w/v BSA/PBS. The 
secondary antibody solution was then removed and cells washed extensively with PBS. Filter 
inserts were then excised and mounted on a glass slide, treating with Fluoroshield™ with 
DAPI mounting medium (Sigma Aldrich (UK)).  
 
Caco-2 cells were also immunostained as per the method above in their undifferentiated 
state, following growth on 12-well plates. Similarly, HEK293 immunostaining was conducted 
after culture on 12-well plates. Confocal microscopy imaging was performed using a Leica 
TCS SP8 confocal microscope using constant laser gain for DAPI and AlexaFluor®488 in all 
immunostained sections.  Where indicated, cells were permeabilised by addition of 0.1% 
Triton X 100 in PBS for 20 minutes at room temperature, in sterile conditions. 
 
Cell uptake studies  
Cell uptake studies were performed in 12-well plates for undifferentiated Caco-2 and HEK293 
cells following 48-hour culture and in Transwell
®
 permeable inserts for polarised and 
differentiated Caco-2 monolayers. For the latter, cells were cultured on Transwell
®
 filter 
inserts for 21-24 days and TEER measured before uptake studies to confirm cell monolayer 
polarity and integrity (typically ~2000 Ωcm
2
) [22]. In both cases, cells were initially incubated 
with HBSS for at least 30 minutes. Samples of GFP-NT, with or without NT, SR142948, or 
GFP were prepared in HBSS and applied to the cells (apical side in case of differentiated, 21-
day filter culture Caco-2 cell monolayers). Cells were incubated with the samples for different 
periods between 30 minutes and 2.5 hours. Thereafter, samples were removed and cells 
washed with cold PBS, followed by cell permeabilisation using 200 μl of 0.1% v/v Triton X-100 
in protein buffer (200 mM Tris, 50 mM NaCl with 200 μl of 1x protease inhibitor stock solution; 
30 minutes incubation). Samples were then centrifuged at 17,900g and supernatant 
quantified by fluorescence measurements using a Tecan Infinite
®
 Pro 200 microplate reader 
(Fluorescein excitation 490 nm, emission 525 nm; GFP excitation 488 nm, emission 509 nm). 
 
Caco-2 monolayer transport studies  
Differentiated Caco-2 monolayers (21-day filter culture)
 
were equilibrated in HBSS for at least 
30 minutes. Cell monolayer TEER was measured (in HBSS) prior to the transport study to 
ensure cell monolayer integrity (typically ~2000 Ωcm
2
; cells with TEER < 1000 Ωcm
2
.were 
excluded from the study). GFP-NT (with or without inhibitors NT and SR142948) or GFP were 
prepared at different concentrations in HBSS and applied to the apical side of the cell 
monolayers. A 100 μl sample of HBSS from the basal side of the Transwell
®
 was taken 
immediately after introduction of the samples as a measure of protein transport through the 
monolayer at time 0 min. 100μl samples were then taken every 30 minutes for three hours, 
replacing the volume of sample taken with fresh HBSS each time. The effective dilution was 
accounted for when calculating concentrations.  Between samples, the Transwell
®
 plate was 
returned to the incubator. Protein transport was quantified using fluorescence as described 
above.  TEER was measured following the transport study to ensure cell monolayer integrity 
was intact. 
 
Statistical Analysis 
The parametric unpaired Students t-test was used to determine statistical significance with 
Welsh's correction to correct for small data sets. 
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Results 
 
Initial experiments focussed on characterisation of NTS1 receptor expression in HEK293 and 
Caco-2 cells. HEK293 cells were chosen as a widely-used tumourigenic model [23] and 
Caco-2 cells represent the classic epithelial gut model [24].  Figure 1 shows confocal 
micrographs of non-transfected HEK293 cells (A and B); transfected HEK293 cells (C and D); 
non-permeabilised, differentiated (21-day filter culture) Caco-2 cells (E and F), permeabilised, 
differentiated Caco-2 cells (G and H) and undifferentiated (2-day plastic culture) Caco-2 cells 
(I and J). A negative control where cell treatment with the primary antibody was omitted is 
shown in each scenario. The data demonstrates a higher level of NTS1 expression in 
transfected HEK293 cells (Figure 1C) than non-transfected HEK293 (Figure 1A) and non-
permeabilised, differentiated Caco-2 monolayers (Figure 1E). Dramatically reduced NTS1 
expression is apparent in permeabilised, differentiated Caco-2 monolayers (Figure 1G) 
compared to non-permeabilised counterparts. Non-differentiated Caco-2 cells do not express 
detectable levels of NTS1 (Figure 1I). We observed qualitatively higher levels of NTS1 
expression on the apical surface of the differentiated Caco-2 monolayer compared to the 
basal surface (Figure 2). 
 
F-NT uptake by non-transfected and transfected HEK293 cells is shown Figure 3, both 
quantitatively by fluorimetry and qualitatively by confocal microscopy. Cells were treated with 
F-NT alone or in the presence of excess free NT or excess SR142948. Free NT competitively 
inhibits all NT receptors, and SR142948 selectively inhibits NTS1 and NTS2. The data shows 
that the uptake of F-NT alone is greater in transfected HEK293 cells (p = 0.026; Figure 3B) 
compared to non-transfected cells (Figure 3A), suggesting that uptake correlates with NTS1 
expression. F-NT uptake is notably higher relative to unconjugated fluorescein. Cell 
internalisation of F-NT is also dramatically reduced by the co-application of excess free NT 
(also shown by confocal microscopy in Figure 3C and D) or SR142948.  
 
GFP-NT uptake by non-transfected and transfected HEK293 cells is shown Figure 4. Cell 
uptake of GFP alone was also tested in these studies to establish the levels of internalisation 
of GFP itself and confirm whether cell uptake of GFP-NT is mediated by NT. The data shows 
a similar pattern in non-transfected (Figure 4A) and transfected cells (Figure 4B), with GFP-
NT showing a higher uptake compared to GFP and also in conditions where GFP-NT was 
applied alone (without excess free NT or SR142948). However, the difference between these 
conditions in non-transfected cells was not statistically significant while in transfected HEK293 
cells this difference was statistically significant (p <0.01), suggesting correlation with relative 
NTS1 expression. Figure 4C and D depict confocal micrographs comparing transfected 
HEK293 cells treated with GFP-NT or GFP-NT plus a 100x excess of NT. Fluorescence due 
to GFP-NT was observed in areas localised around the nucleus in cells treated with GFP-NT 
only and notably lower levels of fluorescence signal were apparent in cell samples exposed to 
excess NT. 
 
NT-conjugated fluorophore internalisation in undifferentiated Caco-2 cells is shown in Figure 
5. Caco-2 cells were incubated with F-NT (Figure 5A) or GFP-NT (Figure 5B) alone, GFP-NT 
or F-NT with excess free NT or excess free SR142948. Cell uptake behaviour of fluorophores 
alone was also performed to provide a comparison with the internalisation of NT-conjugated 
equivalent. Cell uptake of both NT-fluorophores is not affected by competitive NTS receptor 
inhibition via free NT or excess free SR142948. The extent of internalisation seen for each 
condition is comparable to the uptake of fluorophore alone. Confocal micrographs showing 
this uptake are shown in Figure 5C and 5D for F-NT and GFP-NT, respectively (applied 
without competitive inhibitors). The images show minimal F-NT fluorescence (green) within 
the cells, suggesting limited uptake in undifferentiated Caco-2 cells.  
 
Cell uptake of NT-conjugated fluorophores into polarised, differentiated Caco-2 monolayers is 
shown in Figure 6. NT-conjugated fluorophore (F-NT – Figure 6A and GFP-NT – Figure 6B) 
uptake after 150 mins is notably higher compared to the internalisation in the presence of 
excess free NT, as well as the unconjugated fluorophores. Importantly, NT-conjugated 
fluorophore uptake in polarised Caco-2 cells is markedly greater to that in undifferentiated 
cells (Figure 5). This uptake is quantified by measurements at 30-minute intervals for a total 
of 150 minutes (Figure 6C and D). F-NT uptake increases with incubation time up to 60 min, 
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with a plateau apparent at subsequent time points.  GFP-NT entry into cells mirrors the 
pattern observed with F-NT. 
 
Following the demonstration that NT-conjugated fluorophores are capable of internalisation in 
polarised Caco-2 cells, we further probed whether these molecules are able to traverse 
polarised Caco-2 monolayers, as a way of assessing the potential of NT-NTS1 to act as a 
system capable of ferrying therapeutics across the intestinal epithelium. Figure 7 shows the 
apical-to-basolateral transport of F-NT and GFP-NT in Caco-2 monolayers, with samples 
quantified at 30-minute intervals in a 180-minute study. The data shows that both F-NT 
(Figure 7A) and GFP-NT (Figure 7B) traverse Caco-2 monolayers significantly more 
efficiently than the respective unconjugated fluorophores. With both F-NT and GFP-NT a 
concentration-dependent effect is observed, with higher concentrations demonstrating larger 
levels of transport, as well as process saturation with time. Another important observation to 
note when comparing Figures 7A and 7B is that F-NT translocated across polarised Caco-2 
monolayers at markedly higher levels than GFP-NT. 
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Discussion  
 
This work assessed whether a receptor demonstrated to exhibit differential expression in 
cancerous cells can be considered as a system that offers both targeted drug delivery to 
cancer and means of enhancing macromolecular absorption across the gut epithelium 
following oral administration. We utilised both transfected and non-transfected HEK293 cells, 
as well as Caco-2 intestinal epithelial cells as systems with different NTS1 expression 
profiles. Expression of NTS1 in HEK293 cells is consistent with previous studies [25].  NT 
also acts as a local hormone in the gut [3] and hence NTS1 expression in intestinal epithelial 
cells is neither unexpected nor non-physiological [26, 27].  Examining the expression of NTS1 
in transfected HEK293 cells, confocal micrographs reveal high levels of positive fluorescence 
signal in cells immunostained for NTS1 receptor (Figure 1C). Work also showed that 
differentiated, polarised Caco-2 monolayers express the NTS1 receptor (Figure 1E). 
Dramatically reduced NTS1 expression was observed following detergent-mediated 
permeabilisation (Figure 1G), which suggests predominant NTS1 localisation in the plasma 
membrane rather than intracellular membranes. We also show that the expression of the 
NTS1 receptor in non-differentiated Caco-2 cells is undetectable (Figure 1I). It is not 
completely clear why Caco-2 cells exhibit differentiation-dependent expression of NTS1 but 
these findings correlate with observations that NT expression is increased in cells of the villi 
compared to those in the crypts [28].  Differentiated Caco-2 cells are a model of villi 
enterocytes and hence expression of a cognate receptor for NT aligns with the role in gastric 
function [28].  Additionally, similar findings have been reported previously for the class B type 
I scavenger receptor (SR-BI) [29] and vitamin B2 (riboflavin) transporters [30].   
 
Comparing NT-fluorophore uptake behaviour in non-transfected and transfected HEK293 
cells (Figures 3 and 4), the data reveal that cell uptake levels of F-NT or GFP-NT alone are 
significantly greater in transfected HEK293 cells compared to non-transfected cells. Although 
it may be expected that uptake was even higher in transfected cells, it is likely that a cellular 
process downstream of ligand-receptor interactions reaches saturation e.g. receptor 
internalisation.  Uptake of NT-conjugated fluorophores was rapid before eventual saturation.  
NTS1 appears to be degraded following internalisation [18] and NTS1 is regenerated on the 
cell surface via de novo synthesis [5].  Although precise measurements of NTS1 expression 
in native tissue have not been reported, GPCR levels on the cell surface are typically in the 
order of 1x10
3
-1x10
4 
molecules/cell.  Therefore, sufficient uptake of NT-conjugated molecules 
is potentially possible to enable delivery of macromolecules to therapeutically sufficient levels, 
especially considering the large surface area of the intestinal epithelium.  Although limited 
expression of other neurotensin-binding receptors may occur in the cell models used, the 
increases in uptake observed following NTS1 overexpression confirm that this receptor is a 
viable target for drug uptake; it has been demonstrated that NTS2 expression is undetectable 
in HEK293 cells [25].  Competitive NTS1 receptor inhibition with excess free NT or excess 
SR142948 produced a clear inhibition of uptake in both transfected and non-transfected 
HEK293 cells, while with GFP-NT this inhibition was only apparent in transfected HEK293 (a 
statistically significant inhibition was not apparent in non-transfected HEK293 cells, although 
qualitative differences are evident). Inhibition of uptake by excess ligand in transfected 
HEK293 cells was also confirmed by confocal microscopy. These data therefore point to 
NTS1 receptor-mediated uptake of NT-conjugated fluorophores in transfected HEK293 cells.  
The competitive inhibition by NT and SR142948 of uptake of NT-conjugated fluorophores is 
likely to be bimodal.  Firstly, a direct steric competition at the NT-binding site of NTS1 [15] 
and, secondly, receptor internalisation which removes receptors from the cell surface [5]. 
 
NT-conjugated fluorophore internalisation by undifferentiated Caco-2 cells is limited (as 
shown both quantitatively and by confocal microscopy in Figure 5) and comparable to the 
uptake of fluorophore alone. Furthermore, competitive receptor inhibition did not achieve a 
reduction in NT-conjugated fluorophore uptake in undifferentiated Caco-2 cells. These data 
collectively imply that in undifferentiated Caco-2 cells any entry of NT-conjugated 
fluorophores is limited and takes place via a mechanism other than NTS receptor mediated 
internalisation. This is in line with the finding that NTS1 expression was below detectable 
limits in undifferentiated Caco-2 cells, confirming the system’s ability to specifically delivery 
therapeutic payloads predominantly in cells expressing NTS1 receptor. On the other hand, 
polarised Caco-2 monolayers demonstrated uptake of both NT-conjugated fluorophores (F-
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NT and GFP-NT; Figure 6), at significantly higher levels compared to that in undifferentiated 
cells and the unconjugated fluorophores and the internalisation of NT-conjugated 
fluorophores is markedly reduced following competitive receptor inhibition. Differentiated, 
polarised Caco-2 monolayers, which unlike non-differentiated counterparts clearly express 
NTS1, are therefore capable of internalising NT fluorophores via the NTS1 receptor.  
Significant uptake of NT-conjugated fluorophores was observed at 100 nM extracellular 
concentration.  This is consistent with other studies in which branched NT-conjugated drugs 
have EC50 values in the range of 100-400 nM [8].  Low levels of free fluorescein uptake 
observed here are consistent with other studies, with the applied concentration being 
significantly lower than the observed Km for uptake into Caco-2 cells of 7.7 mM [31]. 
 
Following the demonstration that in differentiated Caco-2 monolayers NT-conjugated 
fluorophores internalise through receptor-mediated endocytosis, subsequent work established 
whether NT-conjugated fluorophores have the capacity to translocate across intestinal 
polarised monolayers, which, to our knowledge, is the first time that neurotensin has been 
investigated for such purpose. To achieve successful systemic drug delivery through the 
gastrointestinal mucosa, the therapeutic must be effectively internalised into epithelial cells 
from the gastrointestinal lumen and released at the basal side.  Owing to their 
physicochemical characteristics (molecular size), NT-conjugated fluorophores are not 
expected to be absorbed across the epithelium by diffusion/partitioning into epithelial 
membranes. Rather, macromolecules generally traverse the epithelium by transcytosis 
(paracellular space is considered inadequate for molecules over 1000 Da). Following 
internalisation into epithelial cells, the fate of the cargo is dependent on the cell sorting 
machinery, with the material most likely undergoing a mixture of recycling, delivery to late 
endosomes and lysosomes, or transcytosis. Figure 7 shows that both F-NT and GFP-NT 
traverse differentiated Caco-2 monolayers significantly more efficiently than the respective 
unconjugated fluorophores and in a concentration-dependent manner. Transport process 
saturation was apparent, similarly to the previously reported behaviour of IgG in airway 
epithelial monolayers [32]. This likely correlates with the internalisation of NT receptors, which 
is an established desensitisation mechanism for GPCRs.  Notably, F-NT transport across 
differentiated Caco-2 monolayers was markedly higher than GFP-NT, which suggests an 
effect by the size of the cargo conjugated to NT.  Given previous data [18] it is also possible 
that the NT-conjugated cargoes will escape the lysosomal pathway, increasing the likelihood 
of effective drug delivery. Although NT receptors are expressed in the brain, it is likely that 
many of the NT-macromolecular drug fusions will be too large to cross the blood-brain barrier, 
thus eliminating a potentially significant off-target effect. 
 
In order to best leverage NTS1 as a drug targeting system, it is highly desirable to have a 
comprehensive understanding of its cargo limitations and intracellular trafficking.  Overall, this 
work indicates efficient and receptor expression-dependent uptake of NT-conjugated 
fluorophores by HEK293 and Caco-2 cells, with NTS1 demonstrating potential for uptake of a 
range of molecular weight therapeutics following oral administration. The size dependence of 
the cargo is clear, but it is still possible to deliver relatively large macromolecules (GFP has a 
molecular weight of 27 kDa).  It is also likely that these findings are translatable to other 
GPCRs assuming a common internalisation mechanism.  Further work will focus on 
characterising the method of internalisation, specifically whether drug-ligand conjugates 
utilise a different internalisation pathway to the ligand alone, as found with B12-conjugated 
nanoparticles [33], as well as exploring the upper limit of the size of cargo. In addition, the use 
of more stable analogies of neurotensin will be explored to enhance the translation of these 
findings to the clinical environment. 
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Figure legends 
 
Figure 1. Neurotensin 1 (NTS1) receptor immunostaining in HEK293 and Caco-2 cells.  A) 
Non-transfected HEK293 cells and negative control where cell treatment with primary anti-
NTS1 antibody was omitted B).  C) HEK293 cells transfected with 4l Lipofectamine and 
negative control D). E) Non-permeabilised, differentiated (21-day filter culture) Caco-2 cells 
and negative control F). G) Permeabilised, differentiated (21-day filter culture) Caco-2 cells 
and negative control H). I) Undifferentiated (2-day plastic culture) Caco-2 cells and negative 
control J). Blue staining represents cell nuclei (stained by DAPI) and green staining 
represents NTS1. Immunostaining performed using rabbit, anti-human NTS1 primary 
antibody and goat, anti-rabbit AlexaFluor®488 secondary antibody.  Scale bar = 50m. 
 
Figure 2. Neurotensin 1 (NTS1) receptor immunostaining in differentiated Caco-2 cell 
monolayers (21-day filter culture).  A) DAPI-stained with false-colour imaging indicating depth 
relative to the surface of the Transwell plate (0 m)  B).  Anti-NTS1-immonstained Caco-2 
monolayer with false-colour imaging indicating depth relative to the surface of the Transwell 
plate (0 m).  Immunostaining performed using rabbit, anti-human NTS1 primary antibody 
and goat, anti-rabbit AlexaFluor®488 secondary antibody.  C) Overlay of images in panels A 
and B. 
 
Figure 3. Internalisation of NT-conjugated fluorescein in non-transfected and transfected 
HEK293 cells.   Quantification of F-NT uptake in A) non-transfected and B) pcDNA3.1-NTS1 
transfected HEK293 cells. ‘F-NT’ denotes application of F-NT at 20 nM; ‘F-NT + Free NT’ 
denotes application of 20 nM NT-F with 2 M free neurotensin; ‘F-NT + SR142948’ denotes 
application of 20 nM F-NT with 200 nM SR142948; ‘F’ denotes application of fluorescein at 
20nM. Error bars are representative of mean ±SD and each data point, n=3. Confocal 
microscopy images of pcDNA3.1-NTS1 transfected HEK293 after C) incubation with 20nM F-
NT for 1hr and D) incubation with 20nM F-NT and 2M NT for 1 hr.  Scale bar = 50m. 
 
Figure 4. Internalisation of NT-conjugated GFP in non-transfected and transfected HEK293 
cells.   Quantification of GFP-NT uptake in A) non-transfected and B) pcDNA3.1-NTS1 
transfected HEK293 cells. ‘GFP-NT’ denotes application of GFP-NT at 20 nM; ‘GFP-NT + 
Free NT’ denotes application of 20 nM GFP-F with 2 M free neurotensin; ‘GFP-NT + 
SR142948’ denotes application of 20 nM GFP-NT with 200 nM SR142948; ‘GFP’ denotes 
application of GFP at 20nM. Error bars are representative of mean ±SD and each data point, 
n=3. Confocal microscopy images of pcDNA3.1-NTS1 transfected HEK293 after C) 
incubation with 20nM GFP-NT for 1hr and D) incubation with 20nM GFP-NT and 2M NT for 
1 hr.  Scale bar = 50m. 
 
Figure 5. Uptake of NT-conjugated fluorophores in undifferentiated (2-day plastic culture) 
Caco-2 cells. Quantification of cell internalisation of A) F-NT and  B) GFP-NT. ‘F-NT’ denotes 
application of 20nM F-NT, ‘F-NT + Free NT’ denotes application of 20nM F-NT with 2μM free 
NT, ‘F-NT + SR142948’ denotes application of  20nM F-NT with 200nM SR142948, ‘F’ 
denotes application of 20nM Fluorescein.  ‘GFP-NT’ denotes application of 20nM GFP-NT, 
‘GFP-NT + Free NT’ denotes application of 20nM GFP-NT with 2μM free NT, ‘GFP-NT + 
SR142948’ denotes application of 20nM GFP-NT with 200nM SR142948, ‘GFP’ denotes 
application of 20nM GFP.  Error bars are representative of mean ±SD,n=3. C) Confocal 
micrograph showing F-NT internalisation after incubation with 20nM F-NT for 1hr. D) GFP-NT 
internalisation following incubation with 20nM GFP-NT for 1hr.  Scale bar = 50m.  
 
Figure 6. Uptake of NT-conjugated fluorophores in differentiated Caco-2 cell monolayer (21-
day filter culture).  Quantification of cell internalisation of A) F-NT and B) GFP-NT 150 mins 
after fluorophore application.  Time-dependent uptake of NT-conjugated fluorophores C) F-NT 
and D) GFP-NT.  ‘F-NT’ denotes application of 100nM F-NT, ‘F-NT + Free NT’ denotes 
application of 100nM F-NT with 10μM free NT, ‘F’ denotes application of 100nM Fluorescein.  
‘GFP-NT’ denotes application of 100nM GFP-NT, ‘GFP-NT + Free NT’ denotes application of 
100nM GFP-NT with 10μM free NT, ‘GFP’ denotes application of 100nM GFP.  Data points 
are representative of the mean of n = 3 independent experiments and error bars are 
representative of ± standard deviation (SD). 
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Figure 7. Apical-to-basolateral transport of NT-conjugated fluorophores in differentiated 
Caco-2 cell monolayer (21-day filter culture). A) Transport of F-NT following application at 
20nM, 50nM or 100nM F-NT alone or in combination with 100x free NT to the apical side of 
the monolayers. 100nM F alone was used as a negative control.  Transport was measured 
after 180 minutes. B) Transport of GFP-NT following application at 100nM, 500nM or 1μM 
alone or combination 100nM GFP-NT + 100x excess free NT to the apical side of the 
monolayers. 1μM GFP alone was used as a negative control.  Transport was measured after 
180 minutes.  C) Time course of F-NT transport as described in A).  D) Time course of GFP-
NT transport as described in B). Data points are representative of the mean of n = 3 
independent experiments and error bars are representative of ± SD. 
 
Table 1. Oligonucleotide primer sequences used in this study.  Primers are displayed 5’ to 3’ 
and lowercase nucleotides indicate those which are not complementary to the template 
sequence. 
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Table 1 
 
Primer name Sequence 
AG1 caccatcaccatcacATGGTGAGCAAGGGCGAGGAGCTG 
AG2 ggggggcatatgcatcaccatcaccatcac 
AG3 gttttcatacagttcCTTGTACAGCTCGTCCATGCC 
AG4 tataacgacgcggtttgttttcatacagttcCTTGTACAGC 
AG5 ccggatccttacagaatataacgacgcggtttg 
AG6 GGACGAGCTGTACAAGTAAgaactgtatgaaaacaaacc 
AG7 ggtttgttttcatacagttcTTACTTGTACAGCTCGTCC 
 
